Tumor cells release extracellular microvesicles (MVs) in the microenvironment to deliver biological signals to neighbouring cells as well as to cells in distant tissues. Tumor-derived MVs appear to play contradictory role promoting both immunosuppression and tumor growth and both evoking tumor specific immune response. Recent evidences indicate that tumor-derived MVs can positively impact Dendritic Cells (DCs) immunogenicity by reprogramming DC antigen processing machinery and intracellular signaling pathways, thus promoting anti-tumor response. DCs are considered pivot cells of the immune system due to their exclusive ability to coordinate the innate and acquired immune responses, cross-present exogenous antigens and prime naïve T cells. DCs are required for the induction and maintenance of long-lasting anti-tumor immunity and their exploitation has been extensively investigated for the design of anti-tumor vaccines. However, the clinical grade culture conditions that are required to generate DCs for therapeutic use can strongly affect their functions. Here, we investigated the immunomodulatory impact of MVs carrying the MUC1 tumor glycoantigen (MVsMUC1) as immunogen formulation on clinical grade DCs grown in X-VIVO 15 (X-DCs). Results indicated that X-DCs displayed reduced performance of the antigen processing machinery in term of diminished phagocytosis and acidification of the phagosomal compartment suggesting an altered immunogenicity of clinical grade DCs. Pulsing DCs with MVsMUC1 restored phagosomal alkalinization, triggering ROS increase. This was not observed when a soluble MUC1 protein was employed (rMUC1). Concurrently, MVsMUC1 internalization by X-DCs allowed MUC1 cross-processing. Most importantly, MVsMUC1 pulsed DCs activated IFNγ response mediated by MUC1 specific CD8+ T cells. These results strongly support the employment of tumor-derived MVs as immunogen platforms for the implementation of DC-based vaccines

Tumor derived Microvesicles enhance cross-processing ability of clinical grade Dendritic Cells / Dionisi, Marco; Claudia De Archangelis, ; Battisti, Federico; RAHIMI KOSHKAKI, Hassan; Belleudi, Francesca; Zizzari, ILARIA GRAZIA; Ruscito, Ilary; DI FILIPPO, Alessandra; Torrisi, Maria Rosaria; Napoletano, Chiara; Nuti, Marianna; Rughetti, Aurelia. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - (2018). [10.3389/fimmu.2018.02481]

Tumor derived Microvesicles enhance cross-processing ability of clinical grade Dendritic Cells

DIONISI, MARCO;Federico Battisti;Hassan Rahimi Koshkaki;Francesca Belleudi;Ilaria Grazia Zizzari;Ilary Ruscito;DI FILIPPO, ALESSANDRA;Maria Rosaria Torrisi;Chiara Napoletano;Marianna Nuti;Aurelia Rughetti
2018

Abstract

Tumor cells release extracellular microvesicles (MVs) in the microenvironment to deliver biological signals to neighbouring cells as well as to cells in distant tissues. Tumor-derived MVs appear to play contradictory role promoting both immunosuppression and tumor growth and both evoking tumor specific immune response. Recent evidences indicate that tumor-derived MVs can positively impact Dendritic Cells (DCs) immunogenicity by reprogramming DC antigen processing machinery and intracellular signaling pathways, thus promoting anti-tumor response. DCs are considered pivot cells of the immune system due to their exclusive ability to coordinate the innate and acquired immune responses, cross-present exogenous antigens and prime naïve T cells. DCs are required for the induction and maintenance of long-lasting anti-tumor immunity and their exploitation has been extensively investigated for the design of anti-tumor vaccines. However, the clinical grade culture conditions that are required to generate DCs for therapeutic use can strongly affect their functions. Here, we investigated the immunomodulatory impact of MVs carrying the MUC1 tumor glycoantigen (MVsMUC1) as immunogen formulation on clinical grade DCs grown in X-VIVO 15 (X-DCs). Results indicated that X-DCs displayed reduced performance of the antigen processing machinery in term of diminished phagocytosis and acidification of the phagosomal compartment suggesting an altered immunogenicity of clinical grade DCs. Pulsing DCs with MVsMUC1 restored phagosomal alkalinization, triggering ROS increase. This was not observed when a soluble MUC1 protein was employed (rMUC1). Concurrently, MVsMUC1 internalization by X-DCs allowed MUC1 cross-processing. Most importantly, MVsMUC1 pulsed DCs activated IFNγ response mediated by MUC1 specific CD8+ T cells. These results strongly support the employment of tumor-derived MVs as immunogen platforms for the implementation of DC-based vaccines
2018
DC vaccine; MUC1; antigen processing; cancer immunotherapy; dendritic cells; microvesicles; phagosome; tumor antigens
01 Pubblicazione su rivista::01a Articolo in rivista
Tumor derived Microvesicles enhance cross-processing ability of clinical grade Dendritic Cells / Dionisi, Marco; Claudia De Archangelis, ; Battisti, Federico; RAHIMI KOSHKAKI, Hassan; Belleudi, Francesca; Zizzari, ILARIA GRAZIA; Ruscito, Ilary; DI FILIPPO, Alessandra; Torrisi, Maria Rosaria; Napoletano, Chiara; Nuti, Marianna; Rughetti, Aurelia. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - (2018). [10.3389/fimmu.2018.02481]
File allegati a questo prodotto
File Dimensione Formato  
Dionisi_Tumor-derived-microvesicles_2018.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.76 MB
Formato Adobe PDF
1.76 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1166827
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 27
social impact